Editorial
doi: 10.1056/NEJMe1512602.
Cardiovascular Risk and Sodium-Glucose Cotransporter 2 Inhibition in Type 2 Diabetes
Affiliations
- PMID: 26605932
- DOI: 10.1056/NEJMe1512602
Item in Clipboard
Editorial
Cardiovascular Risk and Sodium-Glucose Cotransporter 2 Inhibition in Type 2 Diabetes
N Engl J Med.
.
No abstract available
Comment on
-
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17. N Engl J Med. 2015. PMID: 26378978 Clinical Trial.
Similar articles
-
[SGLT2 inhibition in type 2 diabetes. New study data for reducing cardiovascular risk].MMW Fortschr Med. 2015 Oct 22;157(18):86-7. MMW Fortschr Med. 2015. PMID: 26985517 Clinical Trial. German. No abstract available.
-
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.N Engl J Med. 2016 Mar 17;374(11):1093-4. doi: 10.1056/NEJMc1600827. N Engl J Med. 2016. PMID: 26981944 No abstract available.
-
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.N Engl J Med. 2016 Mar 17;374(11):1093. doi: 10.1056/NEJMc1600827. N Engl J Med. 2016. PMID: 26981943 No abstract available.
-
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.Am J Med. 2017 Jun;130(6S):S30-S39. doi: 10.1016/j.amjmed.2017.04.009. Am J Med. 2017. PMID: 28526184 Review.
-
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.Am J Cardiol. 2017 Jul 1;120(1S):S28-S36. doi: 10.1016/j.amjcard.2017.05.013. Epub 2017 May 30. Am J Cardiol. 2017. PMID: 28606341 Review.
Cited by
-
Empagliflozin: a wonder drug for the treatment of SIAD?Front Endocrinol (Lausanne). 2024 Oct 7;15:1453159. doi: 10.3389/fendo.2024.1453159. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39435353 Free PMC article. No abstract available.
-
High pericoronary adipose tissue attenuation on computed tomography angiography predicts cardiovascular events in patients with type 2 diabetes mellitus: post-hoc analysis from a prospective cohort study.Cardiovasc Diabetol. 2022 Mar 18;21(1):44. doi: 10.1186/s12933-022-01478-9. Cardiovasc Diabetol. 2022. PMID: 35303857 Free PMC article.
-
Insulin resistance in cardiovascular disease, uremia, and peritoneal dialysis.Trends Endocrinol Metab. 2021 Sep;32(9):721-730. doi: 10.1016/j.tem.2021.06.001. Epub 2021 Jul 12. Trends Endocrinol Metab. 2021. PMID: 34266706 Free PMC article. Review.
-
Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials.Front Endocrinol (Lausanne). 2021 Mar 19;12:619586. doi: 10.3389/fendo.2021.619586. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33815278 Free PMC article.
-
Sustained fasting glucose oxidation and postprandial lipid oxidation associated with reduced insulin dose in type 2 diabetes with sodium-glucose cotransporter 2 inhibitor: A randomized, open-label, prospective study.J Diabetes Investig. 2019 Jul;10(4):1022-1031. doi: 10.1111/jdi.12994. Epub 2019 Feb 19. J Diabetes Investig. 2019. PMID: 30582774 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
